Main menu

London Calling 2023: The potential application of nanopore sequencing for liquid biopsy analysis in children with cancer


Paediatric cancers are the leading cause of death in children post infancy. Analysis of cell-free DNA (cfDNA) to detect circulating tumour-derived DNA (ctDNA) may offer a powerful, minimally invasive tool for diagnosis and comprehensive molecular tumour profiling. Current ctDNA approaches are limited in sensitivity, specificity, scalability, turnaround time, and cost, hindering their implementation into standard clinical care. Here, we exploit whole-genome nanopore sequencing for the multi-modal analysis of cfDNA in paediatric cancer patients. Using liquid biopsy samples from the Stratified Medicine Paediatrics study, we demonstrate the utility of nanopore sequencing to detect clinically relevant somatic aberrations, highly concordant with those detected using matched low-pass Illumina whole-genome sequencing. Additionally, nanopore sequencing allowed read-out of methylation profiles from cfDNA, facilitating tissue-of-origin and oncotype characterisation. Finally, longitudinal monitoring using nanopore sequencing correlated with disease burden and was predictive of disease recurrence, illustrating the strong potential of nanopore-based approaches for clinical disease management in children with cancer.

Authors: Carolin Sauer

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag